Cargando…

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms

Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms. The primary objective of this study is to evaluate the 14- and 28-day mortality associated with cefiderocol. We perfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sajib, Monirul I., Monteforte, Melinda, Go, Roderick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215264/ https://www.ncbi.nlm.nih.gov/pubmed/37237839 http://dx.doi.org/10.3390/antibiotics12050936

Ejemplares similares

640. A Retrospective Assessment of the Effects of Cefiderocol in Patients with Multidrug-resistant Gram-negative Bacterial Infections
por: Sajib, Monirul I, et al.
Publicado: (2022)

554. Clinical Impact of Monoclonal Antibody Therapy with SARS-CoV-2 Infection
por: Mann, Inderjit, et al.
Publicado: (2021)

Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection
por: Mabayoje, Diana A, et al.
Publicado: (2021)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
por: Bonomo, Robert A
Publicado: (2019)

Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
por: Kaye, Keith S., et al.
Publicado: (2023)

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
por: Satlin, Michael J., et al.
Publicado: (2023)

Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
por: Echols, Roger, et al.
Publicado: (2019)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

2434. Healthcare-associated Infections in the Era of COVID-19 Pandemic: An Experience from a Tertiary Care Hospital in Long Island, New York
por: Sajib, Monirul I, et al.
Publicado: (2023)

2759. Cefiderocol vs Best Available Therapy for the Treatment of Carbapenem- Resistant Acinetobacter baumannii
por: Daisey, Gabrielle N, et al.
Publicado: (2023)

Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
por: Sansone, Pasquale, et al.
Publicado: (2022)

1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant Pseudomonas aeruginosa Infections under Cefiderocol Compassionate Use Program
por: Satlin, Michael J, et al.
Publicado: (2021)

Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience
por: Piccica, Matteo, et al.
Publicado: (2023)

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study
por: Matsunaga, Yuko, et al.
Publicado: (2020)

In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience
por: Quirino, Angela, et al.
Publicado: (2023)

1223. The Impact of the COVID-19 Pandemic on the Prevalence of Multidrug-resistant Organisms in Veterans Affairs Nursing Homes
por: Sajib, Monirul I, et al.
Publicado: (2022)

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates
por: Seifert, Harald, et al.
Publicado: (2023)

Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China
por: Lan, Peng, et al.
Publicado: (2022)

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy
por: Rando, Emanuele, et al.
Publicado: (2021)

621. In vitro Ceftazidime: Avibactam Resistance in Carbapenem-Resistant Enterobacteriaceae Isolates
por: Belal, Maymonah, et al.
Publicado: (2019)

Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
Publicado: (2021)

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
por: Oueslati, Saoussen, et al.
Publicado: (2022)

Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction; Antibiotic resistance during and beyond COVID-19; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
Publicado: (2021)

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study
por: Pascale, Renato, et al.
Publicado: (2021)

Clinical experience of cefiderocol
por: Fariñas, María Carmen
Publicado: (2022)

Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant Acinetobacter baumannii
por: He, Yukun, et al.
Publicado: (2022)

Clinical Outcomes Associated with Co-infection of Carbapenem-Resistant Enterobacterales and other Multidrug-Resistant Organisms
por: Tadese, Bekana K., et al.
Publicado: (2022)

2752. Outcomes of Patients with Stenotrophomonas maltophilia infections treated with Cefiderocol in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023)

Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model
por: Matsumoto, Shuhei, et al.
Publicado: (2020)

1273. Efficacy of Cefiderocol against carbapenem-resistant A. baumannii and P. aeruginosa in ventilator-associated pneumonia mouse model
por: Ota, Kenji, et al.
Publicado: (2020)

Aeromonas dhakensis: Clinical Isolates with High Carbapenem Resistance
por: Puah, Suat Moi, et al.
Publicado: (2022)

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021)

The role of cefiderocol in clinical practice
por: Maseda, Emilio, et al.
Publicado: (2022)

Convergent Klebsiella pneumoniae strains belonging to a sequence type 307 outbreak clone combine cefiderocol and carbapenem resistance with hypervirulence
por: Schaufler, Katharina, et al.
Publicado: (2023)

Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study
por: Rando, Emanuele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ku5r3a6au5b0knbc537p9d0ohg